Update 2026: Management of Small Cell Lung Cancer
Consolidation durvalumab after concurrent chemoradiation improves overall survival in limited‑stage small cell lung cancer.
Small cell lung cancer (SCLC) remains a biologically aggressive neuroendocrine carcinoma characterized by early metastatic spread, frequent relapse, and poor long‑term survival. After several decades of limited progress, recent therapeutic advances have begun to reshape management across disease stages. In limited‑stage SCLC, concurrent platinum‑etoposide chemoradiotherapy remains the backbone of curative‑intent treatment, while consolidation durvalumab after chemoradiotherapy has established a new standard for patients without disease progression. In extensive‑stage SCLC, platinum‑etoposide plus a PD‑L1 inhibitor remains the preferred first‑line approach. For selected patients, maintenance lurbinectedin plus atezolizumab and second‑line tarlatamab have expanded treatment options beyond conventional cytotoxic chemotherapy. Intracranial management is evolving, with greater emphasis on baseline brain magnetic resonance imaging, longitudinal surveillance, selective use of prophylactic cranial irradiation, stereotactic radiosurgery in appropriate patients, and neuroprotective strategies during whole‑brain radiotherapy. Biologically, SCLC is increasingly recognized as a heterogeneous disease. Transcriptional subtypes, DLL3, B7‑H3, SEZ6, SLFN11, and circulating tumor DNA are informing clinical trial design and may help refine future treatment selection. This review provides a clinically oriented overview of current standards and emerging therapeutic strategies in SCLC, with attention to evidence quality, toxicity, sequencing, and clinical applicability. It also discusses key unresolved questions that must be addressed before biomarker‑directed and subtype‑informed treatment can be integrated into routine practice.
This review consolidates the latest evidence for small cell lung cancer management, providing clinicians with up‑to‑date recommendations for treatment sequencing and emerging therapies in a disease with historically poor outcomes. By summarizing recent randomized trial data and biomarker advances, the article enables evidence‑based decision making that may improve survival and quality of life for patients with SCLC.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells